ABSTRACT
The lack of therapeutic interventions in aging, neurological and neuro- degenerative diseases has introduced drug repurposing in this domain. The rise of newer approaches and technologies in the field of proteomics, pharmacology, genetics, drug discovery, epigenetics, biochemistry, and molecular biology yielded a lot of greater insights on disease pathology, causal organisms, activation of genes, proteins, enzymes, up/downregulation of receptors, stimulation of signaling cascades, etc. Needless to mention, the advancement indicated in these domains pave the way for the genomic, cellular, and molecular solution of specific disease models along with the systematic scientific approach to gain upper hand against known/unknown causal organisms, and fatal diseases such as cancer, AIDS and neurogenera- tive diseases, etc. Novel chemical entities derived utilizing several instru- mentation approaches such as high-performance liquid chromatography (HPLC), nucleo magnetic resonance (NMR), and mass spectroscopy (MS) and its enhanced versions. However, the drug discovery paradigm towards neurological and neurodegenerative diseases is underway. In this case, the inclusion of drug repurposing would shed light on documented small molecules already available in the market, thereby exploiting its use in neurological and neurodegenerative diseases. Moreover, the incorporation of omics, toxicogenomics, pharmacodynamics, and pharmacokinetics along with drug repurposing would be a viable approach in the drug discovery of neurological and neurodegenerative diseases.
